• Icon Bioscience

    Icon Bioscience, Inc. today announced the FDA has granted orphan drug designation for melphalan intraocular injection for retinoblastoma. The injection is formulated using Icon's Verisome drug delivery technology and is designed to safely deliver therapeutic levels of the drug for an extended period of time via a single intravitreal injection.

    The orphan drug designation provides incentives, such as extended market exclusivity, for companies to develop treatments for diseases that affect fewer than 200,000 people in the United States.